Cancer Therapy Market, By Therapy Type (Chemotherapy, Target Therapy, Immunotherapy, Radiotherapy, and Others), By Cancer Type (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Blood Cancer, Liver Cancer, Thyroid Cancer, Head and Neck Cancer, Skin Cancer, and Others), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Published In : Apr 2024

Code : CMI5335

Pages :174

Formats :

Excel and PDF

Industry : Pharmaceutical

Market Concentration and Competitive Landscape

Cancer Therapy Market Concentration By Players

Close-monitor your Competitor's Move, Request sample copy

Increasing investments and funding for cancer research

Many governments allocate substantial funds to cancer research through grants to universities, medical institutions, and research organizations. National health institutes and cancer research centers are major recipients where innovations in diagnostics, treatments, and prevention methods are frequently developed, there has been increase in the funding provided by government organizations and private investors for conducting research and development activities. For instance, in March 2023, Volastra Therapeutics, a clinical-stage cancer biotechnology company, secured USD 60 million in series A funding. The company intends to use the funds to advance clinical pipeline of both sovilnesib and VLS-1488 in 2023. Sovilnesib is currently in Phase 1 for the treatment of platinum-resistant high-grade serous ovarian cancer, triple-negative breast cancer, and other solid tumors with TP53 mutations. It has also received the U.S. Food and Drug Administration’s fast-track designation in platinum-resistant high grade serous ovarian cancer, underscoring the high unmet need in this population.

Key Players Insights